An Hyeonjun, Ryu Chun-Geun, Jung Eun-Joo, Kang Hyun Jong, Paik Jin Hee, Yang Jung-Hyun, Hwang Dae-Yong
Department of Surgery, Colorectal Cancer Center, Konkuk University Medical Center, Seoul, Korea.
Department of Surgery, Breast Cancer Center, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Ann Coloproctol. 2015 Apr;31(2):63-7. doi: 10.3393/ac.2015.31.2.63. Epub 2015 Apr 30.
The aim of this study is to evaluate the results for the insertion of totally implantable central venous access devices (TICVADs) by surgeons.
Total 397 patients, in whom TICVADs had been inserted for intravenous chemotherapy between September 2008 and June 2014, were pooled. This procedure was performed under local anesthesia in an operation room. The insertion site for the TICVAD was mainly in the right-side subclavian vein. In the case of breast cancer patients, the subclavian vein opposite the surgical site was used for insertion.
The 397 patients included 73 males and 324 females. Primary malignant tumors were mainly colorectal and breast cancer. The mean operation time was 54 minutes (18-276 minutes). Operation-related complications occurred in 33 cases (8.3%). Early complications developed in 15 cases with catheter malposition and puncture failure. Late complications, which developed after 24 hours, included inflammation in 6 cases, skin necrosis in 6 cases, hematoma in 3 cases, port malfunction in 1 case, port migration in 1 case, and intractable pain at the port site in 1 case.
Insertion of a TICVAD under local anesthesia by a surgeon is a relatively safe procedure. Meticulous undermining of the skin and carefully managing the TICVAD could minimize complications.
本研究旨在评估外科医生植入全植入式中心静脉通路装置(TICVADs)的效果。
汇总2008年9月至2014年6月期间因静脉化疗而植入TICVADs的397例患者。该操作在手术室局部麻醉下进行。TICVAD的植入部位主要在右侧锁骨下静脉。对于乳腺癌患者,在手术部位对侧的锁骨下静脉进行植入。
397例患者中,男性73例,女性324例。原发性恶性肿瘤主要为结直肠癌和乳腺癌。平均手术时间为54分钟(18 - 276分钟)。手术相关并发症发生33例(8.3%)。早期并发症15例,包括导管位置不当和穿刺失败。24小时后出现的晚期并发症包括炎症6例、皮肤坏死6例、血肿3例、端口故障1例、端口移位1例以及端口部位顽固性疼痛1例。
外科医生在局部麻醉下植入TICVAD是一种相对安全的操作。细致的皮肤潜行分离和精心管理TICVAD可将并发症降至最低。